Page last updated: 2024-09-04

abiraterone and Neoplasm Metastasis

abiraterone has been researched along with Neoplasm Metastasis in 147 studies

Research

Studies (147)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (0.68)29.6817
2010's109 (74.15)24.3611
2020's37 (25.17)2.80

Authors

AuthorsStudies
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Wei, Q; Xiong, X; Xu, H; Yang, L; Yi, X1
Blanchet, P; Brureau, L; Gourtaud, G; Roux, V; Sadreux, Y; Senechal, C; Vestris, PG1
Agarwal, N; Azad, A; Benzaghou, F; Carles, J; Chowdhury, S; Kerloeguen, Y; Kimura, A; McGregor, B; Merseburger, AS; Mohamed, N; Oudard, S; Pal, S; Panneerselvam, A; Saad, F; Soares, A; Wang, F1
Antonarakis, ES; Arafa, AT; Blader, LR; Engle, J; Jha, G; Ramakrishna, K; Ryan, CJ; Zorko, NA1
Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M1
Artigas, C; Flamen, P; Gil, T; Martinez Chanza, N; Peltier, A; Plouznikoff, N; Sideris, S1
Anceschi, U; Brassetti, A; Calabrò, F; Cindolo, L; De Nunzio, C; Ferriero, M; Flammia, RS; Gallucci, M; Ghahhari, J; Giacinti, S; Guaglianone, S; Leonardo, C; Mastroianni, R; Schips, L; Simone, G; Tema, G; Tubaro, A; Tuderti, G1
Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F1
Condon, B; Liskaser, G; Murphy, DG; Thangasamy, IA1
Aschelter, AM; De Sanctis, V; Macrini, S; Marchetti, P; Marinelli, L; Osti, MF; Reverberi, C; Tronnolone, L; Valeriani, M1
Assenholt, J; Hansen, TF; Madsen, JS; Osther, PJS; Zedan, AH1
Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E1
Banna, GL; Basso, U; Benanti, C; Bimbatti, D; De Giorgi, U; Di Quattro, R; Libra, M; Lipari, H; Malatino, L; Pitrè, A; Rundo, F; Schepisi, G; Urzia, V1
Arenas-Bonilla, AJ; Flores-Martín, JF; Galisteo-Moya, R; Gutiérrez-Tejero, F; Moreno-Jiménez, J; Nieblas-Toscano, D; Ramos-Alaminos, CI; Salas-Moreno, MC; Velarde-Muñoz, C1
Cookson, MS; Parker, DC1
Carretero-González, A; Castellano, D; de Velasco, G; Lora, D; Lorente, D; Manneh, R1
Chen, C; Fang, H; Ge, H; He, H; He, L; Wan, Y; Wang, L; Wang, Y; Wu, Y1
Alvarez-Madrazo, S; Baillie, K; Bennie, M; Cameron, D; Clarke, J; Crearie, C; Jones, RJ; Kavanagh, K; Keel, A; Kurdi, A; Laskey, J; Morrison, D; Mueller, T; Pan, J; Wu, O1
Adelman, CA; Agarwal, N; Burgents, J; Chi, KN; de Bono, J; Fizazi, K; Goessl, C; Hussain, M; Kang, J; Kohlmann, A; Mateo, J; Mehra, N; Olmos, D; Saad, F; Sandhu, S; Sartor, O; Shore, N; Thiery-Vuillemin, A; Twardowski, P; Wu, W1
Csizmarik, A; Keresztes, D; Küronya, Z; Nagy, N; Nyirády, P; Riesz, P; Szarvas, T; Váradi, M1
George, DJ; Higano, CS; Jiao, X; Kalinovsky, J; Miller, K; Saad, F; Sartor, O; Shore, N; Sternberg, CN; Tangirala, K; Tombal, B1
Baston, C; Gingu, C; Guler-Margaritis, SS; Preda, A; Sinescu, I1
Abida, W; Aggarwal, RR; Alumkal, JJ; Attwell, S; Bauman, L; Campeau, E; Feng, FY; Heath, EI; Lakhotia, S; Nanus, DM; Norek, K; Pantuck, AJ; Schweizer, MT; Small, EJ; Snyder, M1
Hamilou, Z1
Ahmed, ME; Alamiri, J; Alom, M; Andrews, JR; Haloi, R; Higa, J; Jeffrey Karnes, R; Joshi, V; Kwon, E; Motterle, G; Shah, PH1
Bensfia, S; Carles, J; Castellano, D; de Bono, J; de Wit, R; Eymard, JC; Facchini, G; Feyerabend, S; Fizazi, K; Geffriaud-Ricouard, C; Helissey, C; Iacovelli, R; Kramer, G; Liontos, M; Melichar, B; Oudard, S; Ozatilgan, A; Poole, EM; Sternberg, CN; Sverrisdóttir, Á; Theodore, C; Tombal, B; Wülfing, C1
Iwamoto, H; Izumi, K; Kadomoto, S; Kadono, Y; Kano, H; Makino, T; Mizokami, A; Naito, R; Shigehara, K; Shimada, T; Yaegashi, H1
Clements, S; Descamps, T; Fischer, S; Gillessen, S; Green, A; McWilliam, A; Oing, C1
Cao, W; He, L; Huang, S; Li, Y; Liu, B; Liu, Y; Long, W; Mai, L; Wu, J; Zhang, Z; Zhou, F1
Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I1
Bothos, J; Cathomas, R; Cho, S; de Bono, JS; Fleming, MT; He, P; Hinrichs, MJ; Liang, M; Martinez, P; Miralles, MS; Petrylak, DP; Rosenbaum, AI; Vashisht, K; Wang, JS; Williams, M; Zhang, Q1
Anand, M; Antonarakis, ES; Armstrong, AJ; Barnett, ES; Berry, WR; Brown, LC; Carbone, EA; Danila, DC; George, DJ; Giannakakou, P; Gill, A; Gregory, SG; Gupta, S; Halabi, S; Healy, P; Jendrisak, A; Luo, J; Nanus, DM; Scher, HI; Schonhoft, JD; Szmulewitz, RZ; Wenstrup, R; Yang, Q; Zhao, JL1
Bratt, O; Fode, M; Kistorp, C; Klausen, TW; Lindberg, H; Nolsøe, AB; Palapattu, G; Sønksen, J; Ternov, KK; Østergren, PB1
Antonarakis, ES; Armstrong, AJ; Barnett, E; Carbone, E; Danila, DC; Dos Anjos, CH; George, D; Gill, A; Gonen, M; Halabi, S; Lu, J; Luo, J; Scher, HI; Schonhoft, JD; Szmulewitz, R; Tagawa, S; Wenstrup, R; Yang, Q; Zhao, JL1
Aksoy, S; Akyol, F; Guler, OC; Hurmuz, P; Kose, F; Muallaoglu, S; Onal, C; Oymak, E; Ozyigit, G; Tilki, B1
Bilen, MA; Brown, JT; Carthon, B; Caulfield, S; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KER; Wan, L; Yantorni, L1
Alibhai, SMH; Breunis, H; Emmenegger, U; Feng, G; Fleshner, N; Gregg, R; Hansen, A; Joshua, A; Timilshina, N; Tomlinson, G; Warde, P1
Chanu, P; Kotani, N; Sane, R; Wade, JR; Wang, N; Wilkins, J; Winkler, J; Yoshida, K1
Ai, J; Bai, S; Lei, H; Liao, D; Peng, G; Qiu, S; Xiong, X; Xu, H; Yang, L; Yi, X1
Balk, SP; Cheng, HH; Chew, F; Kantoff, PW; Kolokythas, O; Marck, BT; Matsumoto, AM; Montgomery, RB; Mostaghel, EA; Nelson, PS; Schweizer, MT; Sharifi, N; Taplin, ME; Yu, EY1
Alexandre, J; Azoulay-Rutman, E; Blanchet, B; Bonnet, C; Boudou-Rouquette, P; Carton, E; Chah Wakilian, A; Goldwasser, F; Golmard, JL; Huillard, O; Noé, G; Orvoen, G; Thomas-Schoemann, A; Vidal, M; Villeminey, C1
Antonarakis, ES; Carducci, MA; Chen, Y; Denmeade, SR; Eisenberger, MA; Lu, C; Luber, B; Luo, J; Maughan, BL; Paller, CJ; Pienta, KJ; Silberstein, JL; Taylor, MN; Wang, H; Zhu, Y1
Carlson, RE; Clark, T; Costello, BA; Dehm, SM; Eckloff, BW; Henzler, C; Hillman, DW; Ho, Y; Hon, T; Huang, H; Jen, J; Jimenez, R; Kohli, M; Lang, JM; Li, Y; Pitot, HC; Quevedo, JF; Sicotte, H; Silverstein, KAT; Sperger, JM; Tan, W; Thai, H; Tseng, E; Van Etten, JL; Vedell, PT; Wang, L; Wieben, ED; Yang, R1
Borza, T; Caram, MEV; Griggs, JJ; Hollenbeck, BK; Miller, DC; Min, HS; Mukherjee, B; Skolarus, TA1
Bianchini, D; de Bono, J; Gilman, A; Hall, E; IJzerman, M; Kolinsky, M; Lorente, D; Mateo, J; Mehra, N; Miranda, M; Omlin, A; Payne, H; Perez, R; Pezaro, C; Porta, N; Ravi, P; Rescigno, P; Terstappen, L; Tunariu, N1
Black, PC; Struss, WJ1
Boccardo, F; Messina, C; Messina, M1
Blasi, L; Cicero, G; De Luca, R; Dieli, F; Pavone, C; Pepe, A; Simonato, A1
Bianchi, E; Caroli, P; Celli, M; Conteduca, V; De Giorgi, U; Fantini, L; Galassi, R; Matteucci, F; Moretti, A; Paganelli, G; Rossi, L; Scarpi, E1
Culig, Z; Eder, I; Eigentler, A; Handle, F; Heidegger, I; Hoefer, J; Klocker, H; Kroon, J; Leo, A; Ploner, C; Puhr, M; Schaefer, G; Van der Pluijm, G1
Brown, JS; Cunningham, JJ; Gatenby, RA; Zhang, J1
Albany, C; Antonarakis, ES; Cao, X; Caram, MV; Chinnaiyan, AM; Cooney, KA; Corn, PG; Daignault-Newton, S; Feng, FY; Hussain, M; Knudsen, KE; Kunju, LP; Lonigro, RJ; Mehra, R; Montgomery, B; Robinson, D; Shevrin, DH; Siddiqui, J; Smith, DC; Stadler, WM; Stein, MN; Tomlins, SA; Twardowski, PW; Whang, YE; Wu, YM1
Folkvaljon, Y; Franck Lissbrant, I; Hjälm-Eriksson, M; Lambe, M; Robinson, D; Stattin, P; Törnblom, M; Ventimiglia, E1
de Bono, JS; Sartor, O1
Antonarakis, ES; Chen, Y; Isaacs, WB; Lai, Z; Liang, C; Lu, C; Luber, B; Luo, J; Piana, D; Silberstein, JL; Wang, H1
Elkon, JM; Lin, J; Millado, KF; Millett, RL1
Gourdin, T1
Bianchini, D; Crespo, M; de Bono, JS; Dolling, D; Figueiredo, I; Flohr, P; Lorente, D; Mateo, J; Miranda, S; Olmos, D; Scher, HI; Seed, G; Terstappen, LWMM1
Aguiar, P; Haaland, B; Lopes, G; Tan, PS1
Ali, R; Chambers, C; Ghosh, S; North, S; Sawyer, M; Shivji, A1
Dowsett, M; Folkerd, E; Johnston, SR; Liccardi, G; Martin, LA; Nikitorowicz-Buniak, J; Pancholi, S; Ribas, R; Simigdala, N1
Fizazi, K; Hamilou, Z; Saad, F1
Akaza, H; Buchan, NC; Chiong, E; Chung, BH; Davis, ID; Kanesvaran, R; Khochikar, M; Le Chuyen, V; Letran, J; Lojanapiwat, B; Murphy, DG; Ng, CF; Ong, T; Pu, YS; Saad, M; Schubach, K; Türkeri, L; Umbas, R; Williams, S; Ye, DW1
Arranz Arija, JA; Bracarda, S; Chan, WY; de Bono, JS; De Giorgi, U; Font, A; Gendreau, S; Jinga, V; Ma, H; Maslyar, DJ; Massard, C; Patel, PH; Radavoi, GD; Riisnaes, R; Rodrigues, DN; Shih, KC; Xu, N1
Saad, F1
Barret, E; Bennamoun, M; Bonnetain, F; Cathala, N; Cathelineau, X; Charton, E; Fenioux, C; Henriques, J; Joulia, ML; Louvet, C; Molitor, JL; Mombet, A; Prapotnich, D; Ropert, S; Rozet, F; Sanchez-Salas, R1
Brown, JS; Cunningham, JJ; Gatenby, RA; Staňková, K1
Chi, KN; Eigl, BJ; Finch, DL; Gleave, ME; Ivanov, N; Khalaf, DJ; Kollmannsberger, CK; Oja, C; Sunderland, K; Vergidis, J; Zulfiqar, M1
Carles, J; Gillessen, S; Heidenreich, A; Heinrich, D; Keizman, D; Miller, K; Nilsson, S; O'Sullivan, JM; Reeves, J; Saad, F; Seger, M; Wirth, M1
Attard, G; Casadio, V; Castro, E; Conteduca, V; De Giorgi, U; Farolfi, A; Gonzalez-Billalabeitia, E; González-Del-Alba, A; Gurioli, G; Hernando, S; Jayaram, A; Lolli, C; Marin-Aguilera, M; Maugeri, A; Medina, A; Mellado, B; Morales-Barrera, R; Olmos, D; Puente, J; Rodriguez-Vida, A; Romero-Laorden, N; Salvi, S; Scarpi, E; Schepisi, G; Vidal, MJM; Villa-Guzmán, JC; Wetterskog, D; Wingate, A1
Shao, N; Ye, DW; Zhu, Y1
James, ND1
Chen, RC; Choudhury, A; Henry, A; Mistry, H; Mitin, T; Pinkawa, M; Spratt, DE1
Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T1
Arasaratnam, M; Bhatnagar, A; Crumbaker, M; Gurney, H; McKay, MJ; Molloy, MP1
Becker, DJ; Becker, KD; Iyengar, AD; Loeb, S; Makarov, D; Ng, J; Punekar, SR; Zaman, A1
Hammerer, P; Manka, L1
Chapin, BF; Ranasinghe, WKB; Reichard, CA1
Chung, JS; Henderson, J; Hovelson, DH; Morgan, TM; Palapattu, GS; Qiao, Y; Reichert, Z; Singhal, U; Spratt, DE; Taichman, RS; Tomlins, SA; Wang, Y; Zaslavsky, AB1
Armstrong, CM; Cai, D; Chen, J; Chen, N; Dai, J; Guo, W; Liu, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Yin, X; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhao, P; Zhu, S; Zhu, X1
Hotte, SJ; Loblaw, DA; Walker-Dilks, C; Winquist, E1
Arlen, PM; Madan, RA1
de Wit, R; Fitzpatrick, JM1
de Morrée, ES; de Wit, R; Mathijssen, RH; Moll, JM; Teubel, W; van Royen, ME; van Soest, RJ; van Weerden, WM; Wiemer, EA1
Balani, G; Gipson, G; Srinivas, S; Tang, J; Wilson, L; Xiang, P; Yu, D; Zhong, L1
Bahl, A1
Altavilla, A; Attard, G; Bianchini, D; de Bono, JS; Ferraldeschi, R; Grist, E; Lorente, D; Mateo, J; Ravi, P; Sideris, S; Smith, A; Wong, S; Zafeiriou, Z1
Blank, PR; Puri, D; Szucs, TD1
Labrie, F1
Bianchi, E; Burgio, SL; Campadelli, E; Carretta, E; Carrozza, F; Conteduca, V; De Giorgi, U; Fabbri, P; Menna, C; Montanari, M; Rudnas, B1
Bellmunt, J; de Bono, JS; Efstathiou, E; Kheoh, T; Li, J; Loriot, Y; Molina, A; Montgomery, B; Ryan, CJ; Scher, HI; Tran, N1
Alimohamed, N; Atenafu, EG; Joshua, AM; Knox, JJ; Leibowitz-Amit, R; Seah, JA; Sridhar, SS; Tannock, IF; Templeton, AJ; Vera-Badillo, FE1
Pal, SK; Sartor, O3
Auchus, RJ; Mundle, SD; Nguyen, S; Yu, MK1
Beer, TM; Graff, JN1
Akaza, H; Imanaka, K; Nakatani, T; Nishiyama, T; Ozono, S; Satoh, T; Tanabe, K; Terai, A; Uemura, H; Yokomizo, A1
Agarwal, N; Antonarakis, ES; Azad, A; Batten, JA; Cheng, HH; Chi, KN; Galsky, MD; Gulati, R; Heath, EI; Leiter, A; Montgomery, RB; Nadal, R; Pal, SK; Rehman, HT; Twardowski, P; Vaishampayan, UN; Yu, EY1
Afshar, M; Al-Alloosh, F; James, ND; Pirrie, S; Porfiri, E; Rowan, C1
Anderson, SA; Azad, AA; Bazov, J; Bell, RH; Chi, KN; Collins, CC; Gleave, ME; Haegert, A; Le Bihan, S; McConeghy, B; Paris, P; Shukin, R; Small, EJ; Thomas, G; Volik, SV; Wang, Y; Wyatt, AW; Youngren, J1
Attard, G; Bianchini, D; Crespo, M; de Bono, JS; Ferraldeschi, R; Figueiredo, I; Flohr, P; Lorente, D; Miranda, S; Nowakowska, K; Riisnaes, R; Rodrigues, DN; Sideris, S; Terstappen, LW; van Dalum, G; Zafeiriou, Z1
Angel, C; D'Costa, I; Rischin, D; Solomon, B; Urban, D1
Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Petrioli, R; Ponchietti, R; Roviello, G1
Antonarakis, ES; Maughan, BL1
Crawford, ED; Higano, CS; Hussain, M; Petrylak, DP; Shore, ND1
Bianco, V; Fiaschi, AI; Francini, E; Francini, F; Laera, L; Petrioli, R; Roviello, G1
Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H1
Bergman, AM; Bos, MM; Chitu, D; de Morrée, ES; de Wit, R; Goey, SH; Hamberg, P; Mathijssen, RH; Nieuweboer, AJ; van der Meer, N; van Soest, RJ1
Albiges, L; Antoun, S; Bayar, A; di Palma, M; Escudier, B; Fizazi, K; Ileana, E; Laplanche, A; Loriot, Y; Massard, C1
Audenet, F; Basset, V; Branchereau, J; de La Taille, A; Flamand, V; Lebdai, S; Lebret, T; Murez, T; Neuzillet, Y; Ploussard, G1
Alesini, D; Basso, U; Caffo, O; Campadelli, E; Conteduca, V; D'Angelo, A; De Giorgi, U; Donini, M; Ermacora, P; Fratino, L; Gasparro, D; Giordano, M; Lo Re, G; Lolli, C; Maines, F; Massari, F; Messina, C; Procopio, G; Ratta, R; Veccia, A; Verderame, F; Zagonel, V1
Wadman, M1
Savage, N1
Antonarakis, ES; Denmeade, SR; Luber, B; Teply, BA1
Brasso, K; Røder, MA; Thim, S; Thortzen, A1
Boegemann, M; Eminaga, O; Herrmann, E; Hinkelammert, R; Krabbe, LM; Mikah, P; Papavassilis, P; Schrader, AJ; Semjonow, A1
Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Höppner, M; Kübler, H; Luppa, PB; Maurer, T; Nawroth, R; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; Thaler, MA; Thalgott, M1
Barsová, L; Bartoš, J; Chalupa, J; Dvořák, J; Forster, J; Hejzlarová, V; Holikova, M; Richter, I; Sochor, M; Stankuš, I1
Divine, GW; Hafron, JM; Hung, J; Hwang, C; Taylor, AR1
Adamo, V; Barni, S; Boccardo, F; Bruno, M; Caffo, O; Caserta, C; Chiuri, VE; De Giorgi, U; De Vincenzo, F; De Vivo, R; Derosa, L; Dinota, A; Facchini, G; Fratino, L; Grassi, P; Messina, C; Mosca, A; Porcu, L; Procopio, G; Ricotta, R; Santini, D; Scavelli, C; Surace, G; Susi, M; Tartarone, A; Verzoni, E; Zaniboni, A1
Antoun, J; Bteich, F; Ghosn, M; Jalkh, A; Kourie, HR1
Baeten, K; Bianchini, D; Crespo, M; Danila, DC; de Bono, JS; Figueiredo, I; Fleisher, M; Flohr, P; Kheoh, T; Lorente, D; Mateo, J; McCormack, R; Miranda, S; Molina, A; Olmos, D; Scher, HI; Seed, G; Terstappen, LW1
Antonarakis, ES; Eshleman, JR; Frick, KD; Luo, J; Markowski, MC1
Balk, SP; Bhasin, M; Bubley, GJ; Domachevsky, L; Kantoff, PW; Lis, R; Marck, BT; Matsumoto, AM; McKay, RR; Montgomery, B; Mostaghel, EA; Taplin, ME; Voznesensky, O; Werner, L; Zhang, Z; Zukotynski, KA1
Biasco, E; Crucitta, S; Danesi, R; Del Re, M; Derosa, L; Falcone, A; Galli, L; Jenster, GW; Miccoli, M; Orlandini, C; Rofi, E; van Schaik, RH1
Srinivas, NR1
Aroasio, E; Berruti, A; Bertaglia, V; Buttigliero, C; DI Maio, M; Scagliotti, GV; Tucci, M; Vignani, F1
Albiges, L; Attard, G; Bianchini, D; de Bono, J; Fizazi, K; Loriot, Y; Massard, C; Mateo, J; Mehra, N; Petrylak, DP; Pezaro, C; Ryan, CJ; Shen, L; Varga, A1
Cristofanilli, M; Hoffman-Censits, JH; Kelly, WK; Kennedy, B; Kilpatrick, D; Leiby, B; Lewis, N; Lin, J; Mu, Z; Patel, SA; Sama, AR; Yang, H; Ye, Z1
Aringer, M; Boegemann, M; Krabbe, LM; Rahbar, K; Schlack, K; Schrader, AJ; Semjonow, A; Steinestel, J; Thomes, S1
Bezrukov, EA; Kondrashina, AV; Rapoport, LM1
Concepcion, RS; Crawford, ED; Finkelstein, SE; Gomella, LG; Keane, TE; Koo, PJ; O'Sullivan, JM; Petrylak, DP; Saad, F; Shore, N; Sieber, P; Slovin, SF; Stone, NN; Tombal, B; Vogelzang, NJ; Yu, EY1
Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R1
Djavan, B; Farr, A; Herout, R; Margreiter, M; Tosev, G1
Bianchini, D; Cheng, T; Chi, KN; Chieffo, N; Chu, L; de Bono, JS; Efstathiou, E; Ellard, SL; Fizazi, K; Flaig, TW; Fléchon, A; Goodman, OB; Hainsworth, JD; Haqq, CM; Harland, S; Hutson, TE; Jones, RJ; Kheoh, T; Logothetis, CJ; Loriot, Y; Mainwaring, P; Molina, A; North, S; Patterson, H; Ryan, CJ; Saad, F; Saleh, M; Scher, HI; Scholz, M; Staffurth, JN; Sternberg, CN; Zivi, A1
Antonarakis, ES; Eisenberger, MA1
Beltran, H; Tagawa, ST1
Sonpavde, G1
Berruti, A; Pia, A; Terzolo, M1
de Bono, JS; Massard, C; Michels, RM; Sartor, O1
Beatty, J; Bell, R; Miller, M; Mohammed, A; Rawlinson, A1
Birtle, A1
Attard, G; Belldegrun, AS; de Bono, JS1

Reviews

34 review(s) available for abiraterone and Neoplasm Metastasis

ArticleYear
Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
    Urologic oncology, 2022, Volume: 40, Issue:1

    Topics: Androgens; Androstenes; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Testosterone; Treatment Outcome

2022
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
    Investigative and clinical urology, 2020, Volume: 61, Issue:Suppl 1

    Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms

2020
Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis.
    Medicine, 2020, Volume: 99, Issue:15

    Topics: Androstenes; Benzamides; Bibliometrics; Bone Neoplasms; DNA Repair; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Publications; Receptors, Androgen; United Kingdom; United States; United States Food and Drug Administration

2020
Molecular underpinnings of systemic treatment resistance in metastatic castration-resistant prostate cancer
    Orvosi hetilap, 2020, 05-01, Volume: 161, Issue:20

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Treatment Outcome

2020
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
    Current opinion in urology, 2020, Volume: 30, Issue:4

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome

2020
The evolving options in metastatic castration-sensitive prostate cancer.
    Current opinion in supportive and palliative care, 2020, Volume: 14, Issue:3

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic

2020
Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
    Prostate cancer and prostatic diseases, 2021, Volume: 24, Issue:4

    Topics: Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life

2021
Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.
    Urologic oncology, 2021, Volume: 39, Issue:11

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2021
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    European urology, 2018, Volume: 73, Issue:1

    Topics: Androgen Antagonists; Androstenes; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Progression-Free Survival; Prostatic Neoplasms; Time Factors; Treatment Outcome

2018
Metastatic Prostate Cancer.
    The New England journal of medicine, 2018, 02-15, Volume: 378, Issue:7

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Drug Resistance, Neoplasm; Humans; Male; Mutation; Neoplasm Metastasis; Prostatic Neoplasms

2018
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
    Current opinion in oncology, 2018, Volume: 30, Issue:3

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic

2018
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
    Prostate cancer and prostatic diseases, 2018, Volume: 21, Issue:4

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Treatment Outcome

2018
Treatment of hormone-naïve metastatic prostate cancer.
    Current opinion in supportive and palliative care, 2018, Volume: 12, Issue:3

    Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic

2018
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
    BJU international, 2019, Volume: 123, Issue:1

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Asia, Eastern; Asia, Southeastern; Combined Modality Therapy; Consensus; Developing Countries; Docetaxel; Humans; Lymph Node Excision; Male; Neoplasm Metastasis; Oceania; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Risk Factors

2019
Germline DNA-repair Gene Mutations and Efficacy of Abiraterone or Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    European urology focus, 2019, Volume: 5, Issue:5

    Topics: Androstenes; Benzamides; DNA Repair; Germ Cells; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2019
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
    European urology oncology, 2019, Volume: 2, Issue:2

    Topics: Androgen Antagonists; Androstenes; Combined Modality Therapy; Docetaxel; Humans; Lymph Node Excision; Male; Metastasectomy; Neoplasm Metastasis; Prostatic Neoplasms; Standard of Care

2019
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
    Der Urologe. Ausg. A, 2019, Volume: 58, Issue:10

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome

2019
Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2013, Volume: 25, Issue:7

    Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids; Tissue Extracts

2013
Recent advances revolutionize treatment of metastatic prostate cancer.
    Future oncology (London, England), 2013, Volume: 9, Issue:8

    Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Hormone Replacement Therapy; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Tissue Extracts

2013
Taxane mechanisms of action: potential implications for treatment sequencing in metastatic castration-resistant prostate cancer.
    European urology, 2014, Volume: 65, Issue:6

    Topics: Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Drug Interactions; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Signal Transduction; Taxoids

2014
Metastatic castration-resistant prostate cancer. Part 1: the challenges of the disease and its treatment.
    European journal of oncology nursing : the official journal of European Oncology Nursing Society, 2013, Volume: 17 Suppl 1

    Topics: Alpha Particles; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Cancer Vaccines; Chlorides; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radium; Taxoids; Tissue Extracts

2013
Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology.
    The Journal of steroid biochemistry and molecular biology, 2015, Volume: 145

    Topics: Androgen Antagonists; Androgens; Androstenes; Androstenols; Animals; Antineoplastic Agents; Benzamides; Dehydroepiandrosterone; Endocrinology; Gonadotropin-Releasing Hormone; Humans; Male; Mutation; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Testosterone; Treatment Outcome

2015
Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.
    The oncologist, 2014, Volume: 19, Issue:12

    Topics: Androstenes; Antineoplastic Agents, Hormonal; Disease Progression; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant

2014
Pharmacotherapeutic management of metastatic, castration-resistant prostate cancer in the elderly: focus on non-chemotherapy agents.
    Drugs & aging, 2014, Volume: 31, Issue:12

    Topics: Aged; Androstenes; Benzamides; Health Services for the Aged; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Tissue Extracts

2014
Androgen pathway resistance in prostate cancer and therapeutic implications.
    Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:10

    Topics: Androgens; Androstenes; Benzamides; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Point Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Splicing; Receptors, Androgen; Signal Transduction

2015
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    The Journal of urology, 2015, Volume: 194, Issue:6

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Survival Rate; Taxoids; Tissue Extracts

2015
[Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
    Nederlands tijdschrift voor geneeskunde, 2015, Volume: 159

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease Progression; Humans; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Testosterone; Treatment Outcome

2015
What do we know about treatment sequencing of abiraterone, enzalutamide, and chemotherapy in metastatic castration-resistant prostate cancer?
    World journal of urology, 2016, Volume: 34, Issue:5

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids

2016
The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
    Urology, 2017, Volume: 104

    Topics: Androgens; Androstenes; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Disease Progression; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Practice Guidelines as Topic; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome

2017
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
    Anti-cancer agents in medicinal chemistry, 2011, Volume: 11, Issue:3

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure

2011
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
    The oncologist, 2011, Volume: 16, Issue:11

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts

2011
The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
    Expert review of anticancer therapy, 2012, Volume: 12, Issue:4

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms

2012
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
    Expert review of anticancer therapy, 2013, Volume: 13, Issue:1

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids

2013
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer.
    BJU international, 2005, Volume: 96, Issue:9

    Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Animals; Drug Evaluation; Humans; Lyases; Male; Mice; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase

2005

Trials

24 trial(s) available for abiraterone and Neoplasm Metastasis

ArticleYear
A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.
    Future oncology (London, England), 2022, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Androstenes; Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Benzamides; Humans; Immune Checkpoint Inhibitors; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Pyridines; Receptor Protein-Tyrosine Kinases

2022
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    The New England journal of medicine, 2020, 05-28, Volume: 382, Issue:22

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzamides; Genes, BRCA1; Genes, BRCA2; Humans; Loss of Function Mutation; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant

2020
A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-15, Volume: 26, Issue:20

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome

2020
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    The Lancet. Oncology, 2020, Volume: 21, Issue:11

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Benzamides; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Taxoids; Treatment Outcome

2020
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-01, Volume: 27, Issue:13

    Topics: Aged; Aged, 80 and over; Androstenes; Antigens, Surface; Benzamides; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Failure

2021
Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients.
    Journal of clinical pharmacology, 2021, Volume: 61, Issue:12

    Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasm Metastasis; Neoplasms; Paclitaxel; Piperazines; Prednisolone; Pyrimidines

2021
Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 11-01, Volume: 27, Issue:21

    Topics: Adrenal Cortex; Adult; Aged; Aged, 80 and over; Androgens; Androstenes; Antineoplastic Agents, Hormonal; Correlation of Data; Drug Combinations; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2021
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Aug-15, Volume: 23, Issue:16

    Topics: Androstenes; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Variation; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA Interference

2017
Prognostic value of 18F-choline PET/CT metabolic parameters in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide.
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Choline; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results; Retrospective Studies

2018
Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer.
    Nature communications, 2017, 11-28, Volume: 8, Issue:1

    Topics: Androgens; Androstenes; Disease Progression; Humans; Male; Models, Theoretical; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Steroid 17-alpha-Hydroxylase; Testosterone; Time Factors; Treatment Failure; Treatment Outcome

2017
Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 04-01, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biomarkers, Tumor; DNA Repair; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prednisone; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-ets; Receptors, Androgen

2018
Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 07-01, Volume: 29, Issue:7

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Follow-Up Studies; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate

2018
Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 02-01, Volume: 25, Issue:3

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Treatment Outcome

2019
Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    European urology, 2019, Volume: 75, Issue:6

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Quality of Life

2019
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
    BMC cancer, 2019, Jan-07, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Treatment Outcome

2019
External validation of a prognostic model predicting overall survival in metastatic castrate-resistant prostate cancer patients treated with abiraterone.
    European urology, 2014, Volume: 66, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; ROC Curve; Survival Rate; Taxoids; Time Factors

2014
Impact of baseline corticosteroids on survival and steroid androgens in metastatic castration-resistant prostate cancer: exploratory analysis from COU-AA-301.
    European urology, 2015, Volume: 67, Issue:5

    Topics: Adrenal Cortex Hormones; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Risk Factors; Survival Analysis; Taxoids

2015
A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:12

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids

2014
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:17

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Treatment Outcome

2015
High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:17

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Outcome Assessment, Health Care; Phenylthiohydantoin; Prognosis; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Subcutaneous Fat

2015
A Phase II Trial of Abiraterone Combined with Dutasteride for Men with Metastatic Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2017, Feb-15, Volume: 23, Issue:4

    Topics: Aged; Androgens; Androstenes; Disease Progression; Drug Resistance, Neoplasm; Dutasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiography; Receptors, Androgen

2017
Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 01-01, Volume: 28, Issue:1

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome

2017
A Phase I/II Study of the Investigational Drug Alisertib in Combination With Abiraterone and Prednisone for Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Abiraterone.
    The oncologist, 2016, Volume: 21, Issue:11

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinase A; Azepines; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Testosterone

2016
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Double-Blind Method; Fatigue; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Survival Analysis; Treatment Outcome

2011

Other Studies

89 other study(ies) available for abiraterone and Neoplasm Metastasis

ArticleYear
Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    The Prostate, 2022, Volume: 82, Issue:2

    Topics: Androstenes; Antineoplastic Agents; Benzamides; Black People; Docetaxel; Guadeloupe; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2022
Clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with abiraterone with or without ongoing androgen deprivation therapy: A retrospective case-control study.
    The Prostate, 2023, Volume: 83, Issue:13

    Topics: Androgen Antagonists; Androstenes; Case-Control Studies; Humans; Male; Neoplasm Metastasis; Progression-Free Survival; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2023
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
    Theranostics, 2019, Volume: 9, Issue:17

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids

2019
Evaluation of PSMA expression changes on PET/CT before and after initiation of novel antiandrogen drugs (enzalutamide or abiraterone) in metastatic castration-resistant prostate cancer patients.
    Annals of nuclear medicine, 2019, Volume: 33, Issue:12

    Topics: Aged; Androstenes; Antigens, Surface; Benzamides; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2019
Managing lines of therapy in castration-resistant prostate cancer: real-life snapshot from a multicenter cohort.
    World journal of urology, 2020, Volume: 38, Issue:7

    Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cohort Studies; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2020
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
    British journal of cancer, 2019, Volume: 121, Issue:12

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome

2019
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. CON: Novel oral agents provide an attractive alternative to chemotherapy in metastatic hormone-sensitive prostate cancer.
    Current opinion in urology, 2020, Volume: 30, Issue:4

    Topics: Administration, Oral; Androstenes; Benzamides; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thiohydantoins

2020
Radiotherapy in metastatic castration resistant prostate cancer patients with oligo-progression during abiraterone-enzalutamide treatment: a mono-institutional experience.
    Radiation oncology (London, England), 2019, Nov-14, Volume: 14, Issue:1

    Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Radiotherapy, Conformal; Receptors, Androgen; Retrospective Studies; Treatment Outcome

2019
Circulating miR-141 and miR-375 are associated with treatment outcome in metastatic castration resistant prostate cancer.
    Scientific reports, 2020, 01-14, Volume: 10, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Case-Control Studies; Circulating MicroRNA; Docetaxel; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Middle Aged; Neoplasm Metastasis; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Survival Rate

2020
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
    The Prostate, 2020, Volume: 80, Issue:5

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate

2020
    Der Urologe. Ausg. A, 2020, Volume: 59, Issue:1

    Topics: Androstenes; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Taxoids

2020
Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2020, Volume: 28, Issue:10

    Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cohort Studies; Humans; Male; Medication Adherence; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2020
Role of the neutrophil/lymphocyte ratio in patients with metastatic castration-resistant prostate cancer treated first-line with abiraterone.
    Actas urologicas espanolas, 2020, Volume: 44, Issue:3

    Topics: Aged; Aged, 80 and over; Androstenes; Humans; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2020
Combination of statin/vitamin D and metastatic castration-resistant prostate cancer (CRPC): a post hoc analysis of two randomized clinical trials.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:11

    Topics: Androstenes; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Vitamin D

2020
Use of record linkage to evaluate treatment outcomes and trial eligibility in a real-world metastatic prostate cancer population in Scotland.
    Pharmacoepidemiology and drug safety, 2020, Volume: 29, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Clinical Decision-Making; Clinical Trials as Topic; Electronic Health Records; Eligibility Determination; Humans; Male; Medical Record Linkage; Middle Aged; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Scotland; State Medicine; Time Factors; Treatment Outcome

2020
Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Density Conservation Agents; Bone Neoplasms; Chemoradiotherapy; Clinical Trials, Phase III as Topic; Denosumab; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Treatment Outcome; Zoledronic Acid

2020
Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
    The Prostate, 2020, Volume: 80, Issue:14

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carboplatin; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure

2020
Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer.
    The Prostate, 2021, Volume: 81, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Docetaxel; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies; Risk Factors; Signal Transduction; Taxoids

2021
Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
    Cancer treatment and research communications, 2020, Volume: 25

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Body Composition; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant

2020
Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.
    Radiation oncology (London, England), 2021, Jan-06, Volume: 16, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Combined Modality Therapy; Cytoreduction Surgical Procedures; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant

2021
Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
    Experimental and molecular pathology, 2021, Volume: 119

    Topics: Androgen Antagonists; Androstenes; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Male; Neoplasm Metastasis; Prostatic Neoplasms; Receptor, Notch1; RNA, Messenger; Transcription Factor HES-1

2021
Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 07-15, Volume: 27, Issue:14

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Chromosomal Instability; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Neurosecretory Systems; Nitriles; Phenotype; Phenylthiohydantoin; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2021
Development and validation of circulating tumour cell enumeration (Epic Sciences) as a prognostic biomarker in men with metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2021, Volume: 150

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Cell Count; Clinical Decision-Making; Humans; Keratins; Leukocyte Common Antigens; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Predictive Value of Tests; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Reproducibility of Results

2021
Stereotactic body radiotherapy for oligoprogressive lesions in metastatic castration-resistant prostate cancer patients during abiraterone/enzalutamide treatment.
    The Prostate, 2021, Volume: 81, Issue:9

    Topics: Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nitriles; Phenylthiohydantoin; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiosurgery; Treatment Outcome

2021
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
    The oncologist, 2021, Volume: 26, Issue:11

    Topics: Androstenes; Black or African American; Docetaxel; Georgia; Health Status Disparities; Hormones; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies

2021
Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    JAMA network open, 2021, 07-01, Volume: 4, Issue:7

    Topics: Aged; Aged, 80 and over; Androstenes; Benzamides; Cognition; Drug Therapy; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium

2021
Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:5

    Topics: Aged; Aged, 80 and over; Androstenes; Comorbidity; Cross-Sectional Studies; Disease-Free Survival; Drug Interactions; Electronic Health Records; Enzyme Inhibitors; France; Humans; Male; Neoplasm Metastasis; Pain; Pharmacists; Polypharmacy; Prevalence; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies

2017
Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Jul-01, Volume: 35, Issue:19

    Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Cohort Studies; Disease-Free Survival; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA, Messenger; Treatment Outcome

2017
Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D.
    Journal of oncology practice, 2017, Volume: 13, Issue:8

    Topics: Aged; Androstenes; Antineoplastic Agents; Benzamides; Catchment Area, Health; Drug Prescriptions; Humans; Insurance Coverage; Male; Medical Oncology; Medicare Part D; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Practice Patterns, Physicians'; Prostatic Neoplasms, Castration-Resistant; United States; Urology

2017
Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey.
    European urology focus, 2018, Volume: 4, Issue:2

    Topics: Androstenes; Biomarkers, Tumor; Clinical Decision-Making; Disease Progression; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Practice Patterns, Physicians'; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Surveys and Questionnaires; Taxoids; Treatment Outcome; Tubulin Modulators

2018
Commentary on: Abiraterone Plus Prednisolone in Metastatic, Castration-sensitive Prostate Cancer.
    Urology, 2017, Volume: 109

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prednisolone; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids

2017
Treatment with abiraterone in metastatic castration-resistant prostate cancer patients progressing after docetaxel: a retrospective study.
    Anti-cancer drugs, 2017, Volume: 28, Issue:9

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids

2017
The Glucocorticoid Receptor Is a Key Player for Prostate Cancer Cell Survival and a Target for Improved Antiandrogen Therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 02-15, Volume: 24, Issue:4

    Topics: Androgen Antagonists; Androstenes; Benzamides; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glucocorticoids; Humans; Kaplan-Meier Estimate; Male; MCF-7 Cells; Neoplasm Metastasis; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Glucocorticoid

2018
Nationwide population-based study on the use of novel antiandrogens in men with prostate cancer in Sweden.
    Scandinavian journal of urology, 2018, Volume: 52, Issue:2

    Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Cross-Sectional Studies; Drug Prescriptions; Educational Status; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Residence Characteristics; Sweden; Time Factors

2018
Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    European urology, 2018, Volume: 74, Issue:2

    Topics: Aged; Androgen Antagonists; Androstenes; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Ataxia Telangiectasia Mutated Proteins; Benzamides; Biomarkers, Tumor; BRCA1 Protein; BRCA2 Protein; Clinical Decision-Making; DNA Mutational Analysis; DNA Repair Enzymes; Genetic Predisposition to Disease; Germ-Line Mutation; GPI-Linked Proteins; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Proteins; Nitriles; Phenotype; Phenylthiohydantoin; Precision Medicine; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Time Factors; Treatment Outcome

2018
Abiraterone is effective and should be considered for the treatment of metastatic castrate-naïve prostate cancer.
    Expert opinion on pharmacotherapy, 2018, Volume: 19, Issue:5

    Topics: Abiraterone Acetate; Androstenes; Anti-Inflammatory Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Taxoids

2018
Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2019, Volume: 25, Issue:6

    Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate

2019
Abiraterone shows alternate activity in models of endocrine resistant and sensitive disease.
    British journal of cancer, 2018, Volume: 119, Issue:3

    Topics: Androstenes; Apoptosis; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Receptors, Androgen; Signal Transduction; Tamoxifen

2018
Improving outcome in patients with prostate and kidney cancer: heading in the right direction?
    Current opinion in supportive and palliative care, 2018, Volume: 12, Issue:3

    Topics: Androstenes; Antineoplastic Agents; Clinical Decision-Making; Humans; Immunotherapy; Kidney Neoplasms; Male; Neoplasm Metastasis; Patient Participation; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein-Tyrosine Kinases

2018
Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.
    BJU international, 2019, Volume: 123, Issue:2

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Dexamethasone; Disease Progression; Drug Substitution; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies

2019
Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer.
    Journal of theoretical biology, 2018, 12-14, Volume: 459

    Topics: Androstenes; Disease Management; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance; Game Theory; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life

2018
Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
    European urology, 2019, Volume: 75, Issue:3

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Humans; Kallikreins; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Spain; Time Factors

2019
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
    European urology focus, 2019, Volume: 5, Issue:2

    Topics: Androstenes; Cost of Illness; Docetaxel; Humans; Male; Molecular Biology; Neoplasm Metastasis; Phenotype; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Tubulin Modulators; Whole Body Imaging

2019
STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer?
    International journal of radiation oncology, biology, physics, 2019, 05-01, Volume: 104, Issue:1

    Topics: Androgen Antagonists; Androstenes; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Radiation Injuries; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Standard of Care

2019
Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:1

    Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Fasting; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostatic Neoplasms, Castration-Resistant

2019
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
    Anticancer research, 2019, Volume: 39, Issue:5

    Topics: Aged; Androstenes; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Terminal Care; Treatment Outcome

2019
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
    European urology, 2019, Volume: 76, Issue:5

    Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Tumor Burden

2019
Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
    Neoplasia (New York, N.Y.), 2019, Volume: 21, Issue:8

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Computational Biology; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2019
AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.
    The Prostate, 2019, Volume: 79, Issue:13

    Topics: Aged; Aldo-Keto Reductase Family 1 Member C3; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Image-Guided Biopsy; Immunohistochemistry; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies

2019
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:18

    Topics: Active Transport, Cell Nucleus; Androstenes; Androstenols; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Nucleus; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Neoplasm; Green Fluorescent Proteins; Humans; Male; Microscopy, Confocal; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Time-Lapse Imaging

2013
New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:6

    Topics: Androstenes; Antineoplastic Agents; Benzamides; Cost-Benefit Analysis; Decision Trees; Drug Costs; Financing, Personal; Humans; Male; Models, Economic; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Quality-Adjusted Life Years; Survival Rate; Taxoids

2014
Abiraterone and metastatic prostate cancer: delays pain onset, cytotoxic therapy, and possibly death.
    Prescrire international, 2014, Volume: 23, Issue:146

    Topics: Androgen Antagonists; Androstenes; Androstenols; Chemical and Drug Induced Liver Injury; Heart Diseases; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms

2014
The use of the EVITA algorithm for clinical assessment of novel agents used in prostate cancer, metastatic melanoma, and systemic lupus erythematosus.
    European journal of clinical pharmacology, 2014, Volume: 70, Issue:8

    Topics: Algorithms; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cancer Vaccines; Humans; Immunosuppressive Agents; Ipilimumab; Lupus Erythematosus, Systemic; Male; Melanoma; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Skin Neoplasms; Tissue Extracts

2014
PSA flare with abiraterone in patients with metastatic castration-resistant prostate cancer.
    Clinical genitourinary cancer, 2015, Volume: 13, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Disease-Free Survival; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Treatment Outcome

2015
Abiraterone acetate in metastatic castration-resistant prostate cancer: a retrospective review of the Princess Margaret experience of (I) low dose abiraterone and (II) prior ketoconazole.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:14

    Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2014
Prostate cancer: the best fit for enzalutamide in metastatic prostate cancer.
    Nature reviews. Clinical oncology, 2014, Volume: 11, Issue:9

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids

2014
Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel.
    Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome

2015
Predictive factors for response to abiraterone in metastatic castration refractory prostate cancer.
    Anticancer research, 2015, Volume: 35, Issue:2

    Topics: Adult; Aged; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms

2015
Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2015, May-15, Volume: 21, Issue:10

    Topics: Aged; Aged, 80 and over; Androstenes; Biomarkers, Tumor; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; DNA, Neoplasm; Docetaxel; Drug Resistance, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation, Missense; Neoplasm Metastasis; Neoplastic Cells, Circulating; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids

2015
Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents.
    British journal of cancer, 2015, Mar-31, Volume: 112, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Benzamides; Cell Line, Tumor; Disease Progression; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen

2015
Abiraterone in metastatic salivary duct carcinoma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2015, Volume: 13, Issue:3

    Topics: Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Humans; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Salivary Ducts; Salivary Gland Neoplasms; Tomography, X-Ray Computed; Treatment Outcome

2015
Tolerability of cabazitaxel in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and abiraterone acetate: a single-institution experience.
    Anti-cancer drugs, 2015, Volume: 26, Issue:8

    Topics: Aged; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Endpoint Determination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Failure

2015
Abiraterone in heavily pretreated patients with metastatic castrate-resistant prostate cancer: final analysis of overall survival.
    Anti-cancer drugs, 2015, Volume: 26, Issue:8

    Topics: Adult; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Survival Analysis

2015
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Future oncology (London, England), 2015, Volume: 11, Issue:21

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Viscera

2015
Treatment: When less is more.
    Nature, 2015, Dec-17, Volume: 528, Issue:7582

    Topics: Androstenes; Benzamides; Castration; Clinical Trials as Topic; Disease Progression; Humans; Male; Neoplasm Metastasis; Nitriles; Patient Selection; Phenylthiohydantoin; Precision Medicine; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Testosterone

2015
Metastasis: Resistance fighters.
    Nature, 2015, Dec-17, Volume: 528, Issue:7582

    Topics: Alternative Splicing; Androgen Antagonists; Androstenes; Benzamides; DNA Repair; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Thionucleotides

2015
The influence of prednisone on the efficacy of docetaxel in men with metastatic castration-resistant prostate cancer.
    Prostate cancer and prostatic diseases, 2016, Volume: 19, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids; Treatment Outcome

2016
A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer.
    Urologic oncology, 2016, Volume: 34, Issue:7

    Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2016
Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer.
    BMC cancer, 2016, Mar-14, Volume: 16

    Topics: Aged; Alkaline Phosphatase; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease-Free Survival; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2016
Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
    BJU international, 2017, Volume: 119, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Chromogranin A; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Phosphopyruvate Hydratase; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome

2017
[Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-resistant Prostate Cancer after Chemotherapy].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2016, Volume: 29, Issue:2

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Benzamides; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies

2016
The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Clinical genitourinary cancer, 2016, Volume: 14, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Disease Progression; Disease-Free Survival; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Survival Analysis; Treatment Outcome

2016
Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study.
    Oncotarget, 2016, Jun-28, Volume: 7, Issue:26

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Follow-Up Studies; Humans; Italy; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Taxoids

2016
Bilateral Choroidal Metastases from Prostate Cancer revealed in a patient under Abiraterone - Fourteen years after diagnosis.
    The Gulf journal of oncology, 2016, Volume: 1, Issue:21

    Topics: Androstenes; Antineoplastic Agents; Disease Progression; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
    European urology, 2016, Volume: 70, Issue:6

    Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Clinical Trials as Topic; Humans; Kaplan-Meier Estimate; Logistic Models; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplastic Cells, Circulating; Prednisone; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant

2016
Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
    The Prostate, 2016, Volume: 76, Issue:16

    Topics: Androstenes; Benzamides; Biomarkers; Bridged-Ring Compounds; Cost Savings; Costs and Cost Analysis; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; Taxoids

2016
The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients.
    European urology, 2017, Volume: 71, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA

2017
Comment on: "Modeling the Relationship between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer".
    Clinical pharmacokinetics, 2017, Volume: 56, Issue:2

    Topics: Abiraterone Acetate; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome

2017
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer.
    Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 2017, Volume: 69, Issue:4

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents, Hormonal; Hormones; Humans; Male; Middle Aged; Neoplasm Metastasis; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Steroids; Treatment Outcome

2017
The Role of the Neutrophil to Lymphocyte Ratio for Survival Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Abiraterone.
    International journal of molecular sciences, 2017, Feb-11, Volume: 18, Issue:2

    Topics: Aged; Androstenes; Antineoplastic Agents; Humans; Kaplan-Meier Estimate; Leukocyte Count; Lymphocytes; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Prognosis; Proportional Hazards Models; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2017
[Concomitant use of abiraterone acetate and triptorelin in patients with castration-resistant prostate cancer].
    Urologiia (Moscow, Russia : 1999), 2016, Issue:1

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Triptorelin Pamoate

2016
New findings in bladder and prostate cancer: highlights from the 26th annual congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria.
    The Canadian journal of urology, 2011, Volume: 18, Issue:2

    Topics: Androstenes; Androstenols; Biomarkers; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Pelvis; Prostatectomy; Prostatic Neoplasms; Radioimmunotherapy; Urinary Bladder Neoplasms

2011
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer.
    Asian journal of andrology, 2011, Volume: 13, Issue:5

    Topics: Androstenes; Androstenols; Antineoplastic Agents; Cancer Vaccines; Clinical Trials, Phase III as Topic; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids

2011
Expanding treatment options for metastatic prostate cancer.
    The New England journal of medicine, 2011, May-26, Volume: 364, Issue:21

    Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase

2011
Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
    Asian journal of andrology, 2011, Volume: 13, Issue:6

    Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, 08-25, Volume: 365, Issue:8

    Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids

2011
Abiraterone and increased survival in metastatic prostate cancer.
    The New England journal of medicine, 2011, 08-25, Volume: 365, Issue:8

    Topics: Adrenocorticotropic Hormone; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase

2011
Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
    Prescrire international, 2012, Volume: 21, Issue:128

    Topics: Androstenes; Androstenols; Drug Interactions; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms

2012
Abiraterone and its place in the treatment of metastatic CRPC.
    Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:1

    Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome

2013
chemdatabank.com